Andere Kunden interessierten sich auch für
![Next Generation Bioprocessing]( "Next Generation Bioprocessing")
Next Generation Bioprocessing60,99 €![Effect of generation G on cancer targeting propensity of PPI dendrimer]( "Effect of generation G on cancer targeting propensity of PPI dendrimer")
Effect of generation G on cancer targeting propensity of PPI dendrimer50,99 €![Utilization of Higher Generation Antibiotics in Private Sectors]( "Utilization of Higher Generation Antibiotics in Private Sectors")
Utilization of Higher Generation Antibiotics in Private Sectors32,99 €![Angiotensin-II Receptor Antagonists: New Generation Antihypertensives]( "Angiotensin-II Receptor Antagonists: New Generation Antihypertensives")
Angiotensin-II Receptor Antagonists: New Generation Antihypertensives46,99 €![Cancer Vaccine Development: Exploration of New Avenues]( "Cancer Vaccine Development: Exploration of New Avenues")
Cancer Vaccine Development: Exploration of New Avenues32,99 €![Plant based vaccine adjuvants]( "Plant based vaccine adjuvants")
Plant based vaccine adjuvants23,99 €![Drug Delivery Systems in Cancer Therapy]( "Drug Delivery Systems in Cancer Therapy")
Drug Delivery Systems in Cancer Therapy240,99 €
Discovery of a potential anticancer therapy is still a challenge to the scientists. Though many different kinds of therapies are developed none of them has lived up to the task to cure cancer completely. Cancer vaccines are found to be the latest discovery in the field of cancer. Although there are number of vaccines undergoing preclinical & clinical trials which are promising to be an effective anticancer therapy. Novel vaccines produce specific immune responses and objective clinical responses with minimal toxicity in phase I/II trials. Advances in gene transfer technology, tumor immunology and better methods of monitoring specific anti tumor immune responses allow the hope that tumor vaccines will be introduced into the clinic, at least in some malignancies resistant to systemic therapy so far such as melanoma and renal cell carcinoma. This book is based on generation of human cancer vaccines that has been tested in phase III clinical trials and shows mechanisms that could contribute to these limited clinical responses, and highlights the challenges faced for development of future vaccines.